Bryn Mawr Capital Management LLC Decreases Position in DaVita Inc. (NYSE:DVA)

Bryn Mawr Capital Management LLC cut its stake in DaVita Inc. (NYSE:DVA) by 61.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,340 shares of the company’s stock after selling 2,160 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in DaVita were worth $200,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its stake in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after purchasing an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares in the last quarter. KBC Group NV lifted its stake in DaVita by 27.3% in the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after purchasing an additional 67,250 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new position in DaVita in the 3rd quarter worth approximately $10,346,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Down 2.5 %

Shares of NYSE DVA opened at $142.33 on Friday. The company has a 50 day simple moving average of $161.03 and a 200-day simple moving average of $157.86. The company has a market capitalization of $11.39 billion, a P/E ratio of 13.25, a P/E/G ratio of 1.14 and a beta of 0.94. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 1 year low of $120.78 and a 1 year high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, equities research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Ratings Changes

Separately, Barclays raised their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, DaVita has an average rating of “Hold” and a consensus target price of $162.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.